Leslie Hanrahan - AMP

We believe this initiative will ultimately lead to new understanding of the underlying causes of lupus along with new therapies for this disease and ultimately an improved quality of life for people living with lupus. For us it is all about the patient! Lupus is  complex and is arguably the most clinically diverse of all autoimmune diseases. Because of this, the scope of the Accelerating Medicines Partnership (AMP)  is tailor made for a collaborative effort among the NIH, industry, academic medical research centers and non profit organization. Lupus was selected for this project because of the lack of effective targeted therapies for the most severe forms of the disease, such as when lupus affects the kidneys or the central nervous system. We at the Lupus Foundation of America know that in order to unlock the mysteries of lupus, collaboration is key to progress. In 2009, the Lupus Foundation of America commissioned a first-of-its-kind report to detail obstacles and provide a roadmap to speed development of new safe, effective and more tolerable treatments for lupus.  The report, authored by the respected health policy research organization The Lewin Group, called for organizing a new coordinated national effort to overcome the barriers that exist which have made developing safe, more tolerable and less toxic treatment options for people with lupus so difficult.  The report recommended that the scientific community and NIH collaborate on a research agenda to provide a clea...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news